### Specifications

**Compatibility with MC 0.0165” / 0.017” ID Microcatheters**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>pEGASUS-350-15-HPC</td>
<td>2.5</td>
<td>3.5</td>
<td>0.0</td>
<td>15</td>
</tr>
<tr>
<td>pEGASUS-350-20-HPC</td>
<td>2.5</td>
<td>3.5</td>
<td>0.0</td>
<td>20</td>
</tr>
<tr>
<td>pEGASUS-350-25-HPC</td>
<td>2.5</td>
<td>3.5</td>
<td>0.0</td>
<td>25</td>
</tr>
<tr>
<td>pEGASUS-350-30-HPC</td>
<td>2.5</td>
<td>3.5</td>
<td>0.0</td>
<td>30</td>
</tr>
<tr>
<td>pEGASUS-450-15-HPC</td>
<td>3.5</td>
<td>4.5</td>
<td>0.0</td>
<td>15</td>
</tr>
<tr>
<td>pEGASUS-450-20-HPC</td>
<td>3.5</td>
<td>4.5</td>
<td>0.0</td>
<td>20</td>
</tr>
<tr>
<td>pEGASUS-450-25-HPC</td>
<td>3.5</td>
<td>4.5</td>
<td>0.0</td>
<td>25</td>
</tr>
<tr>
<td>pEGASUS-450-30-HPC</td>
<td>3.5</td>
<td>4.5</td>
<td>0.0</td>
<td>30</td>
</tr>
</tbody>
</table>

A non-coated bare version is available upon request.

**Next level aneurysm bridging with **HPC** coating technology**

Manufactured by: Femtos GmbH
Universitätsstraße 136
D-44799 Bochum
Tel. +49 234 970 50 320
Fax +49 234 970 50 327

Distributed by: Phenox
Lise-Meitner-Allee 31
D-44801 Bochum
www.phenox.net
Tel. +49 234 36 919 0
Fax +49 234 36 919 19
The pEGASUS Stent System has received the CE Mark (CE 0297). It is not approved for sale nor is available for sale or use in the United States.

Easy positioning is achieved by pEGASUS’ unique open cell design that combines flexibility with advanced kink resistance properties. The balanced radial force along the stent body secures anchoring even in very tortuous anatomy—enabling a stable and dense packing of coils. Visibility is achieved by three proximal and three distal markers.

A 0.017” MC-compatible Nitinol stent structure coated with phenox’ unique antithrombogenic HPC technology—the pEGASUS Stent System allows for the reconstruction of diseased arteries, in particular:

- Saccular and fusiform aneurysms and pseudo-aneurysms in combination with coils
- Vascular dissections in the acute and chronic phases AND if the stenosed segment is dilated via PTA before:
- Atherosclerotic vascular stenoses of intracranial arteries

Key features

- Self-expanding, open-cell stent design for optimal adaptation to different vessel configurations
- Treatment of wide-neck aneurysms, dissections & intracranial stenoses
- Available with the proprietary, antithrombogenic HPC coating technology for increased patient safety
- For vessels from 2.5 mm to 4.5 mm
- Compatible with MC 0.0165” / 0.017” ID

Advanced conformability in complex curvature

The pEGASUS Stent System includes the latest phenox technology. Combines flexibility with stability—less thrombogenic stent surface for increased patient safety.

The HPC effect

Glycocalyx

Natural lining of the endothelium indicating an intact inner vessel wall.

The HPC coating mimics the glycocalyx, thus the platelets do not recognize the surface as a foreign body. Systemic blood coagulation is not disturbed.

Data on File

Platelets

Receptors of platelets detect damages in the vessel wall or foreign bodies. Thus, they can launch the clotting cascade.